Abivax S.A. (0RA9.L) LSE
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
Abivax S.A.
Address
7-11 Boulevard Haussmann
Paris, IF 75009
France
Phone
33 1 53 83 08 41
Website
Sector
Healthcare
Industry
Biotechnology
Employees
69
First IPO Date
September 30, 2016
Key Executives
| Name | Title | Pay | Year Born |
| Marc de Garidel | Chief Executive Officer & Director | 1.15M | 1958 |
| Keith Fournier | Senior Vice President of Global Regulatory Affairs | 0 | N/A |
| David Zhang | Chief Strategy Officer | 0 | 1968 |
| Maurus de la Rosa | Senior Vice President of Research | 0 | N/A |
| Michael Nesrallah | Chief Commercial Officer | 0 | N/A |
| Patrick Malloy | Senior VP & Head of Investor Relations | 0 | N/A |
| Pierre Courteille | Chief Business Officer | 0 | 1969 |
| Timothy Kelly | Chief Technical Officer | 0 | 1969 |
| Heather Dean | Global Head of Sales, Accounts & Commercial Operations | 0 | N/A |
| Ida Hatoum | Chief People & Compliance Officer | 0 | 1975 |
| Hema Keshava | Senior Vice President of Finance | 0 | N/A |
| Kevin Shan | Vice President & Global Head of Biometrics | 0 | N/A |
| Mary Mantock | Senior Vice President & Global Head of Regulatory Affairs | 0 | N/A |
| Chris Rabbat | Chief Medical Officer | 0 | N/A |
| Didier Blondel | EVice President, Chief Financial Officer & Board Secretary | 0 | 1964 |
| Ivan Nunez-Pacheco | Global Head of Patient Services | 0 | N/A |
| James Berger | Global Head of Marketing | 0 | N/A |
| Jeffrey N. Haas | Global Head of Market Access & Pricing | 0 | N/A |
| Jerome Denis | Executive Vice President of Process Development & Manufacturing | 0 | N/A |
Description
Based in Paris, France, ABIVAX Société Anonyme is a biopharmaceutical company dedicated to the discovery and optimization of novel drug treatments. Their research and development efforts primarily target inflammatory conditions, infectious diseases, and various forms of cancer. A central asset in their pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis and Crohn's Disease, and is also being investigated for COVID-19. The same compound is in Phase IIa trials for rheumatoid arthritis, having previously completed a Phase IIa study demonstrating viral remission in individuals with HIV. Additionally, Abivax is advancing ABX 196, an immune-enhancing candidate, through Phase 1/2 clinical trials for the treatment of hepatocellular carcinoma. The company also pursues research programs focused on developing therapies for Dengue fever, influenza, and respiratory syncytial virus. Incorporated in 2013, ABIVAX maintains license agreements with prominent academic and research institutions including the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
